Mineralys Therapeutics Inc (NASDAQ:MLYS) shares, rose in value on Thursday, April 16, with the stock price down by -1.11% to the previous day’s close as strong demand from buyers drove the stock to $13.35.
Actively observing the price movement in the last trading, the stock closed the session at $13.50, falling within a range of $12.9 and $13.87. The value of beta (5-year monthly) was -0.394. Referring to stock’s 52-week performance, its high was $18.38, and the low was $8.24. On the whole, MLYS has fluctuated by -20.30% over the past month.
With the market capitalization of Mineralys Therapeutics Inc currently standing at about $866.10 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-11.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that MLYS’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of MLYS currently trading nearly -5.38% and 7.62% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.66, while the 7-day volatility ratio is showing 8.65% which for the 30-day chart, stands at 10.33%. Furthermore, Mineralys Therapeutics Inc (MLYS)’s beta value is -0.03, and its average true range (ATR) is 1.37.
A comparison of Mineralys Therapeutics Inc (MLYS) with its peers suggests the former has fared considerably weaker in the market. MLYS showed an intraday change of -1.11% in last session, and over the past year, it grew by 10.60%%.
Data on historical trading for Mineralys Therapeutics Inc (NASDAQ:MLYS) indicates that the trading volumes over the past 10 days have averaged 1.09 and over the past 3 months, they’ve averaged 1.09 million. According to company’s latest data on outstanding shares, there are 49.82 million shares outstanding.
Nearly 41.04% of Mineralys Therapeutics Inc’s shares belong to company insiders and institutional investors own 44.68% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.71 million shares as on 2025-03-31, resulting in a short ratio of 2.39. According to the data, the short interest in Mineralys Therapeutics Inc (MLYS) stood at 1001.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.01 million. The stock has risen by 8.45% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MLYS stock heading into the next quarter.
